Mundipharma announces the positive outcome of the European Decentralised Procedure (DCP) for flutiform® k-haler®, a novel treatment for adolescents and adults with asthma

CHMP positive opinion for opioid dependence treatment with Zubsolv®(buprenorphine and naloxone) in Europe

Mundipharma receives CHMP positive opinion for Nyxoid®(intranasal naloxone spray)

Largest ever flutiform®study confirms effectiveness and tolerability in real-world clinical practice: Findings from AffIRM study to be presented at ERS 2017

New data presented at ERS 2017 on flutiform® k-haler® (fluticasone propionate and formoterol), Mundipharma’s novel breath-triggered aerosol inhaler

Mundipharma announces exclusive distribution agreement with Janssen for two primary care diabetes treatments Invokana®(canagliflozin) and Vokanamet®(canagliflozin /metformin) for selected European countries

Mundipharma and CellAct announce new deal for the worldwide development and commercialization of smart chemotherapy CAP7.1

New data show Truxima®(CT-P10) to have comparable efficacy and tolerability in advanced follicular lymphoma to reference i.v. rituximab

Mundipharma signs new deal with Vectura for global development and commercialization of inhaled triple therapy VR2076 for the treatment of asthma and COPD

CHMP announces positive opinion for biosimilar rituximab Truxima® and Mundipharma has secured distribution rights